Skip to main content

Table 1 Patient, disease, and treatment characteristics stratified by BRCA status (n = 61)

From: Assessing frequency and clinical outcomes of BRCA mutated ovarian cancer in Saudi women

Characteristics

 

BRCA mutant n = 25 (41%)

BRCA wild type n = 36 (59%)

P-Value*

N (Frequency)

N (Frequency)

Age at diagnosis

Median (IQR)

 

50 (43–56)

55 (46–66)

0.13

Age ≤ 50

 

14 (56)

15 (41.7)

0.27

Positive personal history of cancer

 

5 (20)

1 (2.9)

0.04

Positive family history of cancer

 

7 (28)

2 (5.6)

0.02

Presence of comorbidities*

 

19 (76)

24 (66.7)

0.43

Histology

High-grade serous

25 (100)

35 (97.1)

0.39

 

Endometrioid

 

1 (2.9)

 

High grade FIGO stage

 

25 (100)

34 (94.4)

0.48

 

Stage 1

6

3

0.65

 

IA

2

0

 
 

IB

2

1

 
 

IC

2

2

 
 

Stage 2

1

4

 
 

IIA

1

1

 
 

IIB

0

3

 
 

Stage 3

15 (58)

21 (55)

 
 

IIIA

0

2

 
 

IIIB

1

2

 
 

IIIC

14

17

 
 

Stage 4

4

10

 

High CA125 (> 35)

 

20 (80)

26 (72.2)

0.46

Initial management

PDS

12 (48)

18 (50)

0.87

 

NAC

13 (52)

18 (50)

 

No. of lines, median (IQR)

 

3 (1–5)

3 (2–4.75)

0.79

Lines of treatment

First line (n = 61)

 

(n = 25)

(n = 18)

 

PBC Non PBC

 

100%

100%

0.26

Second line (n = 49)

 

(n = 18)

(n = 31)

 

PBC

 

88.9

83.4

0.79

Non PBC

 

11.1

16.6

 

Third line (n = 39)

 

(n = 13)

(n = 26)

 

PBC

 

73.1

64

0.42

Non PBC

 

26.9

36

 

Fourth line (n = 23)

 

(n = 10)

(n = 13)

 

PBC

 

50%

23.1%

0.38

Non PBC

 

50%

76.9%

 

Fifth line (n = 13)

 

(n = 7)

(n = 5)

 

PBC

 

–

–

0.68

Non PBC

 

100%

100%

 
  1. Categorical values were compared with the Chi-square test or Fisher’s exact test, and continuous values were described as the median with interquartile range (IQR) and compared using the Mann-Whitney U test
  2. Comorbidities: hypertension, DM, hypothyroidism, bronchial asthma, dyslipidemia, or osteoarthritis. PBC; platinum-based chemotherapy; non PBC, non-platinum-based chemotherapy (Paclitaxel, Liposomal doxorubicin, Etoposide, Gemcitabine, Topotecan, Letrozole, Tamoxifen)